Clinical Trial Approval in Australia.

INVESTIGATIONAL NEW DRUG ALMB-0166GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 21 October 2019 The board of directors (the...

Submission of Clinical Trial Application in Australia

SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0166 IN AUSTRALIA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) August 15, 2019 The Board of...

Orphan-Drug Designation by the U.S. FDA

ALMB-0166 was granted Orphan-Drug Designation by the U.S. FDA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) November 26, 2018 The board of directors (the “Board”) of CSPC Pharmaceutical...